Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus Nivolumab in Advanced Gastric or GEJ Cancer
NCT02999295Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02999295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999295.